Travoprost in children: Adverse effects and intraocular pressure response

Yanovitch, Tammy L.; Enyedi, Laura B.; Schotthoeffer, Erin O’Malley; Freedman, Sharon F.

doi:10.1016/j.jaapos.2008.08.006

Cited by 11 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IOP-lowering efficacy observed with travoprost in this pediatric population was consistent with previous retrospective studies. 14,15 A long-term retrospective study found that latanoprost, another prostaglandin analog, significantly reduced IOP in pediatric patients after 6 months. 5 Comparable to the results of the current report, latanoprost was noninferior to timolol in a 12-week study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension

Dixon

Landry

Venkataraman

et al. 2017

Journal of American Association for Pediatric Ophthalmology and

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Eyelash growth was the most common side effect. 14 In a study of travoprost administered to pediatric patients as an adjunct to other glaucoma medications, 60% of patients responded to travoprost, with a $10% reduction in IOP. The most common adverse event was conjunctival hyperemia.…”

mentioning

confidence: 99%

A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension

Dixon

Landry

Venkataraman

et al. 2017

Journal of American Association for Pediatric Ophthalmology and

View full text Add to dashboard Cite

show abstract

“…These agents are all administered once daily, preferably in the evening; another undoubtable advantage is represented by the extremely rare occurrence of systemic side effects [101,102]: there is only one case report in the literature, as observed by Samant et al in 2016, of abundant sweat secretion over the entire body in a child with coexisting glaucoma and aniridia within 1-2 h of latanoprost application [103]. However, prostaglandin analogues have numerous local side effects including a possible change in iris colour (particularly in patients with mixed-colour irides) [104], blepharitis, ocular irritation and pain, darkening, thickening and lengthening of eyelashes and transient punctate epithelial erosion.…”

Section: Prostaglandin Analoguesmentioning

confidence: 99%

Childhood Glaucoma and Medical Treatment: An Up to Date

Greco¹,

Leto²,

Greco³

et al. 2022

Vision Correction and Eye Surgery

View full text Add to dashboard Cite

Successful treatment of paediatric glaucoma presents many challenges, with IOP control as the first but not the only priority. In paediatric cases medical therapy may play different roles: it could be an important resource for preparing patients for surgical intervention through clearing cornea, it may help control IOP post-operatively or it may be the initial and often the mainstay pillar for clinical management. Besides inadequate IOP reduction, multiple factors conspire against the success of long term medical therapy in paediatric glaucoma: the difficulties with long term adherence, more than in adults, adequate ascertainment of drug-induced side effects and potential adverse systemic effect of protracted therapy among others. Many medications are available for glaucoma management but many of them still carry a warning that “safety and efficacy in paediatric patients have not been established”. An “Up to date” of medical options for childhood glaucoma is the core aim of this chapter, hoping it could be useful for the daily clinical decision process.

show abstract

“…To the best of our knowledge, only one other study, a retrospective study by Yanovitch et al, evaluated efficacy and safety of travoprost 0.004% in a cohort of 57 pediatric patients (75 eyes), affected by congenital and juvenile glaucoma. 80 In this study, travoprost was not used as first-line therapy, and was generally added to other glaucoma medications. From the original cohort, only 26 eyes were included in the efficacy analysis, with a mean baseline IOP of 26.3±6.6 mmHg.…”

Section: Travoprost In Pediatric Populationsmentioning

confidence: 99%

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

Quaranta¹,

Riva²,

Katsanos³

et al. 2015

OPTH

View full text Add to dashboard Cite

Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

show abstract

Travoprost in children: Adverse effects and intraocular pressure response

Cited by 11 publications

References 4 publications

A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension

A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension

Childhood Glaucoma and Medical Treatment: An Up to Date

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

Contact Info

Product

Resources

About